Cyst infection in autosomal dominant polycystic kidney disease: our experience at Toranomon Hospital and future issues

Tatsuya Suwabe

Received: 10 February 2020 / Accepted: 6 July 2020 / Published online: 22 July 2020
© The Author(s) 2020

Abstract
Cyst infection is a frequent and serious complication of autosomal dominant polycystic kidney disease (ADPKD) that is often difficult to treat and can be fatal. However, much is still unknown about cyst infection. Positron emission tomography (PET) is generally recommended for detecting infected cysts, but it has the disadvantages of limited availability, high cost, and radiation exposure. We have devised magnetic resonance imaging (MRI) diagnostic criteria for cyst infection. Lipid-soluble antibiotics such as fluoroquinolones show good penetration into cysts and are recommended for cyst infection. However, we reported that fluoroquinolone-resistant microorganisms showed a high prevalence in cyst infection. We should, therefore, reconsider the empirical use of fluoroquinolones for ADPKD patients with cyst infection. We have suggested a new antibiotic strategy according to the severity of cyst infection. It may be important to consider the drug half-life in serum in addition to the drug susceptibility when selecting antibiotics Cyst drainage is necessary for some patients with refractory cyst infection; however, cyst drainage can be associated with severe adverse events. We suggest adaptation criteria for cyst drainage in patients with cyst infection in ADPKD. Most causative bacteria of cyst infection are enterobacteria, and hematogenous spread via bacterial translocation in the intestine is considered the main cause of cyst infection. Therefore, intestinal flora may be important for cyst infection. The role of the intestinal flora in cyst infection in ADPKD is unknown and should be explored in future research.

Keywords ADPKD · Cyst infection · Infected cyst · Polycystic kidney disease

Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited renal disorder [1, 2], and cyst infection is a frequent and serious complication of ADPKD. It has been estimated that 30–50% of patients with ADPKD experience some form of renal infection during their lifetime [3, 4], although cyst infection leading to hospitalization is much less frequent, occurring in approximately 9% of cases [5]. These infections sometimes become resistant and can be fatal, even when appropriate antibiotics are administered [5–7]. However, much is still unknown about cyst infection in ADPKD, and there are no evidence-based guidelines for the management of cyst infection in these patients [8]. The limited evidence currently available also makes it difficult to identify risk factors for treatment failure [9].

In this article, recent evidence concerning the diagnosis and therapeutic options of cyst infection in cases of ADPKD is reviewed. The clinical features of cyst infection in ADPKD of Japan are also described, and we consider the etiology and origin of cyst infection. We further suggest diagnostic and therapeutic strategies of cyst infection according to our experience in Toranomon Hospital and discuss issues associated with this disease that must be managed in the future.
Clinical features of patients with ADPKD in Japan

In Japan, about 10,000 ADPKD patients are on dialysis, and very few receive kidney or liver transplantation because of a severe donor shortage. This might have increased the proportion of long-term dialysis patients with massive renovascular or hepatomegaly in our study population. For massive enlarged kidney or liver, we perform renal or hepatic transcatheter arterial embolization (TAE). The total kidney volume decreases by about 45% on average at 1 year after renal TAE [10], while the liver volume decreases by about 9.2% on average [11]. The effectiveness of hepatic TAE is limited, which is why markedly fewer patients receive hepatic TAE than renal TAE. In contrast, renal TAE is currently performed worldwide, and various embolic agents are reported to be effective [12–16]. Renal TAE is also conducted before renal transplantation to obtain a sufficient volume reduction for graft implantation [17]. Renal TAE has thus become a standard option for the treatment of enlarged kidneys in ADPKD in Japan.

Cyst infection is a relatively frequent complication in ADPKD patients, especially in patients on long-term dialysis with hepatomegaly in Japan. For example, a total of 492 ADPKD patients (2278 episodes) were admitted to Toranomon Hospital with a diagnosis of cyst infection during the period from January 2002 to December 2019. The number of patients with ADPKD who were referred to our hospital was 2602 persons (4461 episodes) aside from cases of scheduled hospitalization for evaluations after renal TAE, so the number of patients hospitalized by cyst infection accounted for 18.9% of all ADPKD patients referred to our hospital, and the number of cases of hospitalization due to cyst infection accounted for 51.1% of all hospitalized episodes in patients with ADPKD in our hospital. Some patients were admitted several times due to cyst infection. One patient was admitted more than 50 times with a diagnosis of cyst infection since 2004 in our hospital. Renal cyst infection may unlikely occur after renal TAE [5, 19], hepatic cyst infection, by contrast, is a much more serious problem in Japan.

Identification of infected cysts in ADPKD

We recently devised MRI diagnostic criteria for cyst infection (Additional file 1) [20]. The possibility of cyst infection can be assessed using our criteria even if causative microorganisms are not identified by culture of the cyst contents [21]. In our criteria, the detection of four intracystic features on abdominal MRI (a high signal intensity [SI] on diffusion-weighted imaging [DWI], fluid-fluid level, wall thickening, and gas) and the assessment of changes over time are important for detecting cyst infection (Fig. 1a–d). The disadvantage of using MRI to detect infected cysts is the low specificity, especially in patients with organomegaly [22]. Intracystic gas is specific for cyst infection, but its sensitivity is only 1.1% (Table 1). A high intracystic SI on DWI showed a sensitivity of 86.4%, but its specificity was relatively low at 33.3% (Tables 2, 3). Both the specificity and sensitivity of a fluid–fluid level and wall thickening were about 80%. However, the specificity of these MRI features decreased as the total liver and kidney volume (TLKV) increased, falling to 65.8% in patients with organomegaly (TLKV > 8500 cm$^3$). A cyst diameter > 5 cm was deemed useful for detecting severely infected cysts that needed drainage, and the specificity was increased by combining it with the other four MRI findings. We concluded that we could identify most cases of severe cyst infection that required drainage by combining the 4 MRI features with abdominal pain at the same location plus changes from previous MRI findings and a cyst
Fig. 1  a MRI findings (T1WI, T2WI, and DWI) in a patient with cyst infection. The infected renal cyst shows a higher intensity on DWI compared with normal cysts, but it is difficult to identify on T1WI and T2WI. b MRI findings (T1WI, T2WI, and DWI) in a patient with cyst infection. A fluid-fluid level and cyst wall thickening can be seen. The infected renal cyst shows a higher intensity on DWI and T1WI than normal cysts, while it has a lower intensity on T2WI. c MRI findings (T1WI, T2WI, and DWI) in a patient with cyst infection. Obvious cyst wall thickening can be seen. The infected cyst is iso-intense on T1WI, T2WI, and DWI. d MRI findings (T1WI, T2WI, and DWI) in a patient with cyst infection. Gas is seen on T1WI, T2WI, and CT. The infected renal cyst shows a higher intensity on DWI compared with normal cysts, while it has a lower intensity on T2WI and T1WI. Sited from Suwabe T, et al. BMC Nephrol. 2016 Nov 9;17(1):170

Table 1  Number of episodes with each MRI feature of cyst infection, and the sensitivity and specificity of each MRI feature

| MRI Feature                                      | Cases (n = 88) | Controls (n = 147) | Sensitivity | Specificity |
|--------------------------------------------------|----------------|--------------------|-------------|-------------|
| High SI on DWI (%)                               | 86.4           | 66.7               | 86.4        | 33.3        |
| Fluid-fluid level (%)                            | 50.0           | 12.9               | 50.0        | 87.1        |
| Wall thickening (%)                              | 48.3           | 10.9               | 48.3        | 89.1        |
| Fluid-fluid level or wall thickening (%)         | 84.1           | 19.7               | 84.1        | 80.3        |
| Gas (%)                                          | 1.1            | 0                  | 1.1         | 100         |
| At least one of these four features (%)          | 100            | 68.0               | 100         | 32.0        |
| High SI on DWI with diameter > 5 cm (%)           | 69.3           | 15.6               | 69.3        | 84.4        |
| Fluid-fluid level or wall thickening with diameter > 5 cm (%) | 72.7           | 8.8                | 72.7        | 91.2        |
| At least one of these four features with diameter > 5 cm (%) | 83.0           | 18.4               | 83.0        | 81.6        |

Sited from Suwabe et al. BMC Nephrol (2016) 9:17(1):170
Table 2  Number of episodes in cases with positive MRI features of cyst infection and intracystic changes, and the sensitivity of each MRI feature and intracystic changes in four groups stratified by TKLV

| TKLV   | Number of episodes M/F | Age | Renal function (Dialysis %) | High SI on DWI (%) | Fluid-fluid level (%) | Wall thickening (%) | Fluid-fluid level or wall thickening (%) | Gas (%) | At least one of these four features (%) | High SI on DWI with diameter > 5 cm (%) | Fluid-fluid level or wall thickening with diameter > 5 cm (%) | At least one of these four features with diameter > 5 cm (%) |
|--------|------------------------|-----|----------------------------|-------------------|----------------------|-------------------|------------------------------------------|---------|----------------------------------------|------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| TKLV < 3000 cm³ | All episodes in cases (n = 88) | 88 (39/49) | 64.6 ± 10.7 | 80.2 | 86.4 | 50.0 | 48.3 | 84.1 | 1.1 | 100 | 69.3 | 72.7 | 83.0 |
| TKLV = 3000 to < 5500 cm³ | Cases with TKLV < 3000 cm³ (n = 13) | 13 (0/13) | 63.4 ± 17.1 | 92.3 | 92.3 | 38.5 | 53.9 | 84.6 | 0 | 100 | 53.9 | 53.9 | 61.5 |
| TKLV = 5500 to 8500 cm³ | Cases with TKLV 3000 to < 5500 cm³ (n = 39) | 39 (16/23) | 65.5 ± 11.0 | 76.9 | 82.5 | 55.0 | 45.0 | 85.0 | 2.5 | 100 | 67.5 | 75.0 | 85.0 |
| TKLV > 8500 cm³ | Cases with TKLV 5500 to 8500 cm³ (n = 17) | 17 (8/9) | 66.6 ± 7.7 | 70.6 | 82.4 | 58.8 | 47.1 | 82.4 | 0 | 100 | 82.4 | 82.4 | 100.0 |
| TKLV > 8500 cm³ | Cases with TKLV > 8500 cm³ (n = 17) | 17 (14/3) | 61.8 ± 5.8 | 88.2 | 94.4 | 38.9 | 52.9 | 83.3 | 0 | 100 | 94.4 | 72.2 | 77.8 |

*p value*<0.0001 NS

TKLV total kidney and liver volume, NS not significant

Sited from Suwabe T, et al. BMC Nephrol. 2016 Nov 9;17(1):170

| TKLV   | Number of controls without MRI features of cyst infection and intracystic changes, and the specificity of each MRI feature and intracystic changes in four groups stratified by TKLV |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TKLV < 3000 cm³ | All controls (n = 147) | Controls with TKLV < 3000 cm³ (n = 39) | Controls with TKLV 3000 to < 5500 cm³ (n = 35) | Controls with TKLV 5500 to <8500 cm³ (n = 35) | Controls with TKLV >8500 cm³ (n = 38) |
| Number of patients M/F | 147 (62/85) | 39 (14/25) | 35 (14/21) | 35 (19/16) | 38 (15/23) |
| Age (years) | 53.3 ± 11.0 | 50.3 ± 14.7 | 52.3 ± 8.8 | 55.4 ± 9.5 | 55.4 ± 9.1 |
| Renal function (Dialysis %) | 49.0 | 5.1 | 31.4 | 74.3 | 86.8 |
| Without high SI on DWI (%) | 33.3 | 69.2 | 37.1 | 14.3 | 10.5 |
| Without fluid-fluid level (%) | 87.1 | 100.0 | 82.9 | 82.9 | 79.0 |
| Without wall thickening (%) | 89.1 | 100.0 | 94.3 | 82.9 | 71.4 |
| Without fluid-fluid level or wall thickening (%) | 80.3 | 100.0 | 82.9 | 71.4 | 65.8 |
| Without gas (%) | 100 | 100 | 100 | 100% | 100 |
| None of the four features (%) | 32.0 | 69.2 | 34.3 | 14.3 | 7.9 |
| Without high SI on DWI (diameter > 5 cm) (%) | 84.4 | 100.0 | 94.3 | 77.1 | 65.8 |
| Without fluid-fluid level or wall thickening (diameter > 5 cm) (%) | 91.2 | 100.0 | 94.3 | 94.3 | 76.3 |
| Without at least one of the four features (diameter > 5 cm) (%) | 81.6 | 100.0 | 91.4 | 74.3 | 60.5 |

*p value*<0.0001 NS

TKLV total kidney and liver volume, NS not significant

Sited from Suwabe T, et al. BMC Nephrol. 2016 Nov 9;17(1):170
diameter >5 cm with almost 100% sensitivity and at least
84.4% specificity.

As mentioned above, acute or chronic intracystic hemor-
rhaging may be the most difficult disease to differentiate
from infected cysts, which decreases the specificity of MRI
for the diagnosis of infected cysts. However, renal intracystic
hemorrhaging rarely occurs in patients who have received
renal TAE, and hepatic intracystic hemorrhaging is even
rarer than renal intracystic hemorrhaging. Therefore, the
specificity of features of infected cyst on MRI increases in
patients who have received renal TAE. Most of the patients
in our hospital have received renal TAE, and we do not usu-
ally encounter substantial problems associated with the diag-
nosis of cyst infection by MRI.

Poor prognostic factors influencing cyst infection
in ADPKD

We investigated the clinical factors related to the duration
of hospitalization and death due to cyst infection [23]. All
ADPKD patients who underwent cyst drainage, nephrect-
omy or partial hepatectomy at Toranomon Hospital from
January 2004 to March 2016 in whom a cyst fluid analysis
showed bacteria or neutrophils indicating definite cyst infec-
tion were retrospectively reviewed. A total of 243 patients
with cyst infection were enrolled, including 104 men and
139 women (mean age: 62.6 ± 10.0 years). Seventeen
patients died of a definite cyst infection.

A multivariate logistic regression analysis revealed that
hepatomegaly, positive cyst contents in culture, and a high
white blood cell (WBC) count were significantly associ-
ated with death from cyst infection. Death was significantly
more likely if patients had massive hepatomegaly (≥ 5113.2
ml) compared with mild hepatomegaly (< 1898.7 ml)
(odds ratio: 38.1; 95% confidence interval [CI] 2.9–492.6,
p = 0.0004). A multivariate Cox proportional hazards anal-
ysis revealed that old age, long dialysis duration, hepatic
TAE, high serum total cholesterol level, high WBC count,
and hepatomegaly were significantly associated with longer
hospitalization for cyst infection. Hepatomegaly was the
strongest factor, being associated with both death and longer
hospitalization due to cyst infection. Dialysis was not a sta-
tistically significant factor associated with death from cyst
infection in this series, probably due to a lack of a sufficient
number of patients. But it is generally said that patients with
ESRD have disorders of the immune systems [24] and a
majority of the patients with serious cyst were on dialysis.
Therefore, ESRD may be a poor prognostic factor for cyst
infection.

Causative microorganisms for cyst infection
and susceptibility to lipid-soluble antibiotics

We conducted a study to determine the profile of the micro-
organisms causing cyst infection in ADPKD and their sus-
ceptibility to lipid-soluble antibiotics [21]. This retrospective
study reviewed all ADPKD patients admitted to Toranomon
Hospital with a diagnosis of cyst infection from January 2004 to March 2014. All patients who underwent cyst drainage and had positive cyst fluid cultures were enrolled. Patients with positive blood cultures who satisfied our criteria for cyst infection or probable infection were also enrolled. There were 99 cases with positive cyst fluid cultures and 93 cases with positive blood cultures. Gram-negative bacteria accounted for 74–79% of the isolates in all groups, except for patients with positive hepatic cyst fluid cultures (Fig. 2). The susceptibility of *Escherichia coli* to fluoroquinolones was very low in patients with hepatic cyst infection, especially those with frequent episodes and those with hepatomegaly (Table 4). Fungi were detected in two cases. As such, fluoroquinolone-resistant microorganisms showed a high prevalence in cyst infection. This result suggests that lipid-soluble antibiotics are not always effective for cyst infection and it is important to identify causative microorganisms in order to avoid the overuse of fluoroquinolones.

**Origin of renal or hepatic cyst infection**

We previously reported that most microorganisms causing cyst infection were enterobacteria [21], which is consistent with the findings of other studies [5, 25]. It is generally believed that the route of cyst infection is hematogenous spread or retrograde infection. However, fewer patients had positive urine cultures in our study than in other reports, and renal cyst infection was equally common in men and women [6, 21]. This may be because the majority of our dialysis patients who have undergone renal TAE were completely anuric, and urinary tract infection may be rare in completely anuric patients. In addition, the remarkable elevation of biliary enzymes was not seen in most episodes of hepatic cyst infection. These findings suggest that the majority of cyst infections in our study population might have been caused by hematogenous spread rather than retrograde infection. This hypothesis is supported by our case report in which *Salmonella* grew from samples of blood and cyst contents in ADPKD patients with *Salmonella* enteritidis cultured from stool samples [26].

In about half (14 of 26 episodes) of hepatic cyst infection cases, microorganisms cultured from the blood did not completely match the isolates from the cyst fluid [21]. We usually perform cyst drainage and cyst fluid culture after the administration of antibiotics for several weeks. However, blood cultures are usually performed just after the onset of cyst infection, which might explain why the cyst fluid isolates differed from those detected by blood cultures. Microorganisms detected by blood culture might reflect the ones causing early infection, while those

### Table 4 Susceptibility of major gram-negative causative bacteria to lipid-soluble antibiotics

| Isolates                                      | LVFX (%) | CPFX (%) | TS (%) |
|-----------------------------------------------|----------|----------|--------|
| **Cyst fluid culture in renal cyst infection**|          |          |        |
| *Escherichia coli* (11 episodes in 11 patients) * | 54.5 (6/11) | 54.5 (6/11) | 63.6 (7/11) |
| *Klebsiella* (2 episodes in 2 patients)        | 100 (2/2) | 100 (2/2) | 100 (2/2) |
| *Enterobacter* (n = 0)                         | NA       | NA       | NA     |
| *Pseudomonas aeruginosa* (n = 0)               | NA       | NA       | NA     |
| **Cyst fluid culture in hepatic cyst infection**|          |          |        |
| *Escherichia coli* (23 episodes in 20 patients) † | 21.7 (5/23) | 21.7 (5/23) | 65.2 (15/23) |
| *Klebsiella* spp. (9 episodes in 9 patients) ‡  | 88.9 (8/9) | 88.9 (8/9) | 88.9 (8/9) |
| *Enterobacter* spp. (4 episodes in 4 patients) | 75.0 (3/4) | 75.0 (3/4) | 100 (4/4) |
| *Pseudomonas aeruginosa* (5 episodes in 3 patients) | 60.0 (3/5) | 60.0 (3/5) | NA     |
| **Blood culture in renal cyst infection**      |          |          |        |
| *Escherichia coli* (11 episodes in 10 patients) § | 63.6 (7/11) | 66.7 (6/9) | 63.6 (7/11) |
| *Klebsiella* (8 episodes in 8 patients)        | 100 (8/8) | 100 (8/8) | 100 (8/8) |
| *Enterobacter* (2 episodes in 2 patients)      | 100 (2/2) | 100 (2/2) | 100 (2/2) |
| *Pseudomonas aeruginosa* (n=0)                 | NA       | NA       | NA     |
| **Blood culture in hepatic cyst infection**    |          |          |        |
| *Escherichia coli* (n = 20) ‡                | 30.0 (6/20) | 31.6 (6/19) | 65.0 (13/20) |
| *Klebsiella* spp. (13 episodes in 13 patients) | 92.3 (12/13) | 92.3 (12/13) | 100 (13/13) |
| *Enterobacter* spp. (8 episodes in 7 patients) | 87.5 (7/8) | 87.5 (7/8) | 100 (7/7) |
| *Pseudomonas aeruginosa* (5 episodes in 5 patients) | 60.0 (3/5) | 60.0 (3/5) | NA     |

LVFX levofloxacin, CPFX ciprofloxacin, TS trimethoprim-sulfamethoxazole, NA not applicable

*Extended spectrum beta lactamase (ESBL) was detected in *E. coli* from 3 renal cyst fluid cultures

†ESBL was detected in *E. coli* from 6 hepatic cyst fluid cultures

‡ESBL was detected in *Klebsiella* from 1 hepatic cyst fluid culture

§ESBL was detected in *E. coli* from 4 blood culture of renal cyst infection

∥ESBL was detected in *E. coli* from 4 blood culture of hepatic cyst infection

Sited from Suwabe et al. Eur J Clin Microbiol Infect Dis. 2015;34(7):1369-79
detected by cyst fluid culture might be responsible for late infection. Invasion of intestinal microorganisms can occur repeatedly, with invasion of resistant microorganisms surviving in the intestines after antibiotic therapy leading to late infection. Accordingly, enterobacteria may play important roles in the onset of cyst infection. Further investigations on this topic are needed.

**Antibiotic therapy for cyst infection**

Drug delivery is independent of glomerular filtration when cysts do not communicate with the renal tubules, so water-soluble antibiotics do not penetrate such cysts well [3, 27–29]. In contrast, lipid-soluble antibiotics show good penetration into cysts and are recommended for the treatment of infected cysts in ADPKD [3, 27, 29–33]. As mentioned above, Gram-negative rods, such as *E. coli*, are the main causative agents of cyst infection in ADPKD [5, 6, 25]. Among lipid-soluble antibiotics, fluoroquinolones and trimethoprim–sulfamethoxazole have a broad range of activity against Gram-negative rods and are generally used to treat cyst infection. Trimethoprim–sulfamethoxazole is not recommended for patients with end-stage renal disease [34], so we often select fluoroquinolones as first-line antibiotics for cyst infection. However, we reported that fluoroquinolone-resistant microorganisms showed a high prevalence in cyst infection [21].

Carbapenem therapy may be required for some cyst infections that are resistant to lipid-soluble antibiotics, especially in patients with ESBL-positive bacteria. Mero-penem (MEPM) is a representative carbapenem with a broad spectrum of activity, but little is known about the penetration of such newer carbapenems into the cysts of ADPKD patients. Therefore, we investigated the penetration of MEPM into infected cysts of ADPKD patients [35]. Between August 2013 and January 2014, 10 ADPKD patients (14 infected cysts) receiving MEPM at Toranomon Hospital underwent drainage of infected cysts, and definite cyst infection was confirmed through the detection of neutrophils by a cyst fluid analysis. The serum concentration of MEPM was measured just after intravenous administration and compared with that in fluid aspirated from infected cysts. In the patients undergoing cyst drainage, the mean serum MEPM concentration was 35.2 ± 12.2 μg/ml (range: 19.7–59.2 μg/ml), while the mean cyst fluid concentration of MEPM in the drained liver cysts (*n* = 12) or kidney cysts (*n* = 2) was 3.03 ± 2.6 μg/ml (range: 0–7.3 μg/ml) (Fig. 3). In addition, the mean cyst fluid/serum MEPM concentration ratio was 9.46% ± 7.19% (range: 0–18.8%) (Fig. 4). There was no relationship between the cyst fluid concentration of MEPM and the time until drainage after MEPM administration or between the cyst fluid/serum MEPM concentration ratio and the time until drainage (Fig. 5). These findings suggest that MEPM shows poor penetration into infected cysts in ADPKD patients. However, MEPM is clinically effective for cyst infection in most ADPKD patients. One of the reasons for this apparent discrepancy might be that the minimum inhibitory concentration (MIC) of MEPM is relatively low for most bacteria. For example, the MIC₉₀ of MEPM for *E. coli* and *Klebsiella pneumonia* (typical gram negative bacteria) was only 0.03 μg/ml according to a survey performed in Japan [36]. However, the MIC₉₀ of MEPM is high for some bacteria, e.g. 16 μg/ml for *Pseudomonas aeruginosa*. The intracystic MEPM concentration might
not reach the effective level for such bacteria, which may explain why MEPM is not always effective for cyst infection. If cyst infection does not respond to antibiotic therapy with MEPM, we should consider that the intracystic MEPM concentration may be too low for it to be effective against the causative bacteria and should also remember that *Enterococcus* spp. is frequently found in patients with refractory cyst infection [21].

Fungi were only detected in two episodes in our present series, but we should additionally consider this possibility in patients with refractory infection. There are a few reports of cyst infection induced by fungi from other facilities as well [37–39].

**Our antibiotics strategy for cyst infection at Toranomon Hospital**

It is important to identify causative microorganisms in order to avoid empirical therapy, so blood cultures should be performed before administering antibiotics, along with urine cultures in patients with pyuria and cyst fluid cultures after cyst drainage. Antibiotic therapy should be started as soon as possible if cyst infection is suspected because the death rate was reported to be high when infection was caused by multiple microorganisms or when there were multiple infected cysts [21]. If the causative bacteria are identified, appropriate antibiotics should be selected according to the bacteria [21]. If the causative microorganisms are not identified, fluoroquinolones may be used empirically. However, our findings suggest that we should reconsider the empirical use of fluoroquinolones for ADPKD patients with cyst infection [21].

Fluoroquinolones should be used for severe cyst infection, because water-soluble antibiotics, including carbapenem, might not achieve adequate concentrations inside the infected cyst and may therefore not be effective enough. However, water-soluble antibiotics are usually effective for managing mild cyst infection. Indeed, there are some articles that have reported the effectiveness of water-soluble antibiotics for cyst infection in ADPKD [5, 21, 23, 40]. Shankar et al. reported that severe emphysematous polycystic infection by *Klebsiella pneumoniae* was treated by penicillin [40]. We actually administered β-lactamines for 55–73% of the patients with positive cyst content culture or blood culture tests in our hospital [21].

Fluoroquinolones should be preferentially administered in cases of severe cyst infection and should be avoided in cases of mild cyst infection as first-line antibiotics in order to prevent their abuse. Below, we suggest antibiotics regimens according to the severity of cyst infection. When determining the severity of cyst infection, we should consider the general condition of the patient, including their blood pressure and body temperature, clinical history, laboratory test findings (e.g. white blood cell count and serum CRP level), and imaging features of infected cysts. Patients with sepsis and disseminated intravascular coagulation (DIC) should be considered to have a severe infection. The definition of mild or severe cyst infection still remains controversial and it is currently up to each individual physician to make such a diagnosis. The clearly defined definition of mild or severe cyst infection should, therefore, be elucidated in the future. We have prepared a flowchart concerning the suggested treatment for cyst infection in ADPKD patients (Fig. 6). This flowchart is based on our experience, and it will be necessary to evaluate its usefulness and generalizability in the future.

**For mild cyst infection**

The intravenous administration of water-soluble antibiotics, such as Penicillin- and Cephem-based antibiotics, is usually effective for mild cyst infection. It is important to choose antibiotics with a broad spectrum covering Gram-negative bacteria in terms of drug susceptibility. In addition, the time above the minimum inhibitory concentration (MIC) is an important determinant of the activity of β-lactams. To ensure sufficient time above the MIC of antibiotics in infected cysts, it may be important to consider the drug half-life, as the intracystic antibiotics concentration may increase and be sustained for a longer duration the longer its serum concentration is sustained. It is necessary to accumulate further evidence regarding the association between the drug half-life and its effectiveness against cyst infection. We have described the half-life of some antibiotics in patients with a normal renal function and patient on hemodialysis based on

---

**Fig. 5** Relationship between the MEPM concentration ratio and time to drainage after administration of MEPM. Black circles: patients with hepatic cyst infection, Red circles: patients with renal cyst infection. Sited from Hamanoue S, et al. BMC Nephrol. 2018;19(1):272
Diagnosis of cyst infection

Mild cyst infection
Antibiotic therapy should be initiated as soon as possible. Intravenous administration of water-soluble antibiotics, such as Penicillin- and Cepham-based antibiotics, may be effective. It may be important to consider the drug half-life in serum in addition to the drug susceptibility when selecting antibiotics. If initial treatment fails, fluoroquinolones should be considered. Once the causative bacteria is identified, antibiotic treatment for the causative microorganisms should be administered.

Severe cyst infection
Antibiotic therapy should be initiated as soon as possible. Fluoroquinolone should be administered in combination with the intravenous administration of water-soluble antibiotics with a broad spectrum (third- or fourth-generation cepham or carbapenem, etc.). High-dose antibiotics therapy should be considered. Vancomycin may be necessary in some cases. Once the causative bacteria is identified, antibiotic treatment for the causative microorganisms should be administered.

For antibiotic-resistant cases, cyst drainage should be considered.

Antibiotic therapy should be continued until the symptoms have completely improved.

Fig. 6 Flowchart of the treatment for cyst infection in ADPKD

| Drug serum half-life of antibiotics | Half-life in patients with a normal renal function (h) | Half-life in patients on hemodialysis (h) |
|-------------------------------------|-----------------------------------------------------|-----------------------------------------|
| Sulbactam/Ampicillin (SBT/ABPC)     | SBT 1.0/ ABPC 1.3<sup>a</sup>                      | SBT 13.4/ABPC 17.4<sup>a</sup>          |
| Tazobactam/Piperacillin (TAZ/PIPC)  | TAZ 0.9/ PIPC 1.0<sup>a</sup>                      | TAZ 7.4/PIPC 2.1<sup>a</sup>            |
| Cefazolin (CEZ)                     | 2.5<sup>a</sup>                                    | 26.4<sup>b</sup>                        |
| Cefotiam (CTM)                      | 1.0<sup>c</sup>                                    | 2.7<sup>c</sup>                         |
| Cefotaxime (CMZ)                    | 1.0 –1.2<sup>a</sup>                               | 6.2 –7.4<sup>a</sup>                    |
| Ceftazidime (CAZ)                   | 1.7<sup>d</sup>                                    | 13<sup>e</sup>                          |
| Cefotaxime (CTX)                    | 1.0<sup>a</sup>                                    | 2.4<sup>a</sup>                         |
| Ceftriaxone (CTRX)                  | 7–9<sup>e</sup>                                    | 12–24<sup>c</sup>                      |
| Ceftapime (CFPM)                    | 2<sup>d</sup>                                      | 18<sup>d</sup>                          |
| Flomoxef (FMOX)                     | 0.76<sup>a</sup>                                   | ω: 0.4, β: 17.4<sup>a</sup>             |
| Meropenem (MEPM)                    | 1.1<sup>c, e</sup>                                 | 6–8<sup>c, e</sup>                      |
| Imipenem (IPM)                      | 1.0<sup>e</sup>                                    | 4.0<sup>c, e</sup>                      |

<sup>a</sup>Sited from medical package insert of each drug
<sup>b</sup>Blum RA, Kohli RK, Harrison NJ, Schentag JJ. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemotherapy. 1989;33:1470-6
<sup>c</sup>Fogel MA, Nussbaum PB, Feintzeig ID, Hunt WA, Gavin JP, Kim RC. Cefazolin in chronic hemodialysis patients: a safe, effective alternative to vancomycin. Am J Kidney Dis. 1998;32:401-9
<sup>d</sup>Bennett WM. Clin Pharmacokinet. Drug Data Handbook 3rd edition. . Auckland: Adis International company; 1998
<sup>e</sup>United States Pharmacopeial Convention : Drug Information for the Health Care Professional 27th edition Vol 1 . 2007
<sup>f</sup>Aronoff GR. Drug Prescribing in Renal Failure : Dosing Guidelines for Adults and Children 5th edition. Philadelphia: American College of Physicians; 2007
the Medication guidebook for patients on dialysis (Table 5). As shown in Table 5, the half-life of antibiotics differs markedly, especially in patients on dialysis.

The efficacy of the oral administration of water-soluble antibiotics is still unclear, as the bioavailability of these antibiotics may be low [41, 42]. At present, avoiding the oral administration of water-soluble antibiotics may be best. More cases describing the oral administration of water-soluble antibiotics should be accumulated in the future.

**For severe cyst infection**

Lipid-soluble antibiotics should be used for severe cyst infection. However, fluoroquinolone-resistant microorganisms show a high prevalence in cyst infection. Therefore, we suggest that the intravenous administration of water-soluble antibiotics with a broad spectrum be used as well, in combination. Third- or fourth-generation cephem and carbapenem can be promising options for such cases. High-dose antibiotic administration may also be necessary in moribund patients to obtain a higher serum concentration of antibiotics, as high-dose antibiotics are administered to patients with bacterial meningitis [43]. However, high-dose antibiotics therapy may be associated with more frequent side effects than lower doses. We, therefore, need to balance the effectiveness and side effects of high-dose antibiotics therapy and build a consensus concerning the use of high-dose antibiotics for severe cyst infection. Vancomycin may be necessary if combined therapy of lipid-soluble antibiotics and carbapenem is not effective, as *Enterococcus* spp. is a frequently identified causative bacterium.

We have suggested an example antibiotic regimen for severe cyst infection in patients on hemodialysis whose causative bacteria is unknown (Fig. 7). High-dose MEPM and levofloxacin (LVFX) are administered together. If this is not sufficiently effective, vancomycin (VCM) should be added, as *Enterococcus* spp. is a frequent causative bacteria of cyst infection. The dose of antibiotics should be high at first and can later be reduced to a safer dose after the patient’s serious condition is improved.

We evaluated the efficacy of this antibiotic treatment regimen in our hospital. We analyzed the clinical outcome of patients who developed septic shock between 2016 and 2019. During this period, 8 patients died among 15 patients (53.3%) who did not receive combined antibiotic therapy based on our regimen (high dose carbapenem + fluoroquinolones ± Vancomycin). In contrast, only 1 patient died from fungus infection among 8 patients (12.5%) who had received combined antibiotic therapy based on our regimen during the same period. There findings suggest that our strategy may be useful in most patients with severe cyst infection, but we need to accumulate more cases to confirm this. We should also build a consensus concerning the target dose and duration of such intensive antibiotic treatment. If the causative bacteria are able to be identified, antibiotic therapy should be adjusted according to the bacteria. However, we should be careful about superinfection due to the presence of additional microorganisms, since superinfections may occur in patients with a severe cyst infection [21].

**Cyst drainage**

The indication of cyst drainage is still controversial [44]. No evidence supporting the indication of cyst drainage has been gathered. Generally speaking, cyst drainage is recommended if a fever persists for one to two weeks despite appropriate antimicrobial therapy [45]. Cyst drainage may also be recommended for large, infected cysts exceeding 5 cm in diameter [5]. We have suggested adaptation criteria for cyst drainage in ADPKD cases with cyst infection (Table 6). We consider severe cyst infection should be indicated for cyst drainage because the amount of bacteria is large and it can be more serious and even fatal when it relapses. Patients demonstrating cyst infection with many repeat episodes are also recommended to undergo cyst drainage. We performed 1,038 cyst drainage procedures from 2004 to 2019. We experienced several cases with severe adverse events related to cyst drainage (Table 7).

---

**Table 6** Suggested criteria for cyst drainage in cyst infection in ADPKD

| Infection resistant to antibiotics therapy (a fever that persists for 1–2 weeks despite appropriate antimicrobial therapy) |
| Large infected cyst exceeding 5 cm in diameter |
| Severe cyst infection (sepsis, disseminated intravascular coagulation [DIC], etc.) |
| Cyst infection with many repeat episodes |
Given that cyst drainage can be associated with severe adverse events, we should establish adaptation criteria for cyst drainage in order to justify this procedure. The definitive operative procedure has not yet been established either. We usually place an indwelling catheter in the infected cysts for one week, and wash out the cyst contents with saline solution every day. The timing for cyst drainage also remains controversial. We believe that we should avoid performing cyst drainage when patients are in a poor condition because the patients’ condition can worsen and become fatal just after cyst drainage due to the effects of surgical invasion. Therefore, we usually perform cyst drainage after patients first show an improvement in their overall condition even if antibiotic therapy is slightly effective. There are also some patients who do not respond to antibiotic therapy at all and, therefore, need to receive cyst drainage as soon as possible. We should continue to explore the best surgical procedures and optimal timing for performing cyst drainage in the future.

**Surgical resection**

Nephrectomy or partial hepatectomy is performed for refractory cyst infection in which cyst drainage is technically impossible. However, nephrectomy or partial hepatectomy can be associated with severe adverse events, so surgical indications should be considered carefully.

**Effectiveness of renal transarterial embolization for renal cyst infection**

We previously reported that the incidence of renal cyst infection might decrease if adequate renal volume (RV) reduction can be achieved by renal TAE [10, 23]. From 2004 to 2016, 807 patients underwent renal TAE in our hospital, 16 of whom (2.0%) had definite renal cyst infection. A total of 61 patients had definite renal cyst infection in our hospital from 2004 to 2016. Among them, 16 had undergone renal TAE before, while 45 had not undergone renal TAE before. In contrast, 379 patients underwent hepatic TAE in our hospital from 2004 to 2016, 48 of whom (12.7%) had a definite hepatic cyst infection. The ratio of patients who had a definite renal cyst infection among those who received renal TAE was significantly lower than the ratio of patients who had a definite hepatic cyst infection among those who received hepatic TAE (2.0% vs. 12.7%, $p < 0.0001$). This fact might support our hypothesis that renal TAE prevents renal cyst infection in ADPKD. As mentioned above, renal cysts are infected through the hematogenous spread of bacteria. Renal TAE occludes renal arteries as much as possible. If the renal blood flow is shut off completely after renal TAE, renal cyst infection can theoretically be prevented. However, a few patients still suffer from renal cyst infection. Indeed, in our series, 16 patients had definite renal cyst infection from 2004 to 2016. This may be because the renal blood flow was not shut completely after renal TAE. Indeed, some patients still release small amounts of urine even after renal TAE. In addition, the nutrition status improves after renal TAE as the food intake increases [46], which may also help prevent cyst infection.

However, we experienced patients with severe renal cyst infection that occurred just after renal TAE in whom renal cyst infection might have still been active [47]. The renal blood flow decreases after renal TAE, so antibiotics may be unlikely to reach the infected renal cysts through the blood flow, and the antibiotics concentration in infected cysts may, therefore, not achieve the level needed in such patients after renal TAE. The cyst infection may consequently worsen after renal TAE. Renal cyst infection can progress rapidly after renal TAE, and it should not be performed in patients with active cyst infection. Further studies are needed in order to clarify whether or not renal TAE can prevent renal cyst infection in ADPKD patients.

In contrast to renal TAE, hepatic TAE may not prevent hepatic infection at all. In addition, hepatic TAE was not significantly associated with death from cyst infection, but it was significantly associated with a longer hospitalization duration in our series [23]. This may be because hepatic arteries are occluded only partially by hepatic TAE, and the invasion of bacteria into hepatic cysts through hepatic arteries is thus not prevented. We were unable to assess the impact of hepatic TAE on the incidence of cyst infection in that study, so further investigations will be needed to determine whether or not hepatic TAE influences the risk of cyst infection.

**Prevention of cyst infection**

As mentioned above, hematogenous spread via bacterial translocation in the intestine is considered to be the main

---

| Number of patients who underwent cyst drainage: 1054 between January 2014 to June 2019 | Percentage of all cyst drainage (%) |
|---------------------------------|---------------------------------|
| Number of events                | Percentage of all cyst drainage (%) |
| Plueroperitoneal communication  | 7                               | 0.66                          |
| Bile fistula                    | 6                               | 0.57                          |
| Peritonitis                     | 5                               | 0.47                          |
| Pneumothorax                    | 4                               | 0.38                          |
| Severe intracystic bleeding     | 2                               | 0.19                          |
| Bile duct hemorrhagic cholangitis | 1                             | 0.09                          |
| Gastrointestinal perforation    | 1                               | 0.09                          |
| Sudden death                    | 3                               | 0.28                          |
| All                             | 29                              | 2.75                          |
cause of cyst infection [21]. Most causative bacteria are enterobacteria, so the intestinal microbiome may be important for cyst infection. In fact, intestinal probiotic bacteria, such as lactobacillus and bifidobacteria, are not causative bacteria of cyst infection [21]. The intestinal microbiome and innate immune system cooperate in the eradication of bacterial infection [48, 49]. Probiotic administration may be effective for preventing cyst infection, as probiotics administration has been shown to be effective for preventing colitis [50]. Furthermore, specific probiotic lactobacillus strains reportedly influence the host immune system by promoting immunoglobulin A (IgA) production [51]. The role of intestinal microbiome on cyst infection in ADPKD is unknown, and further research on this topic is needed.

Some patients developed cyst infection after they caught a cold or enteritis. Bacterial translocation may be more likely to occur in patients with a poor physical condition. In fact, we experienced a patient who developed a cyst infection after enteritis, and his causative bacteria of the cyst infection was exactly the same as that of enteritis [26]. This underscores the importance of maintaining a good physical condition. The nutrition status may also be important, as it may be related to immunity [52, 53]. It is known that malnutrition in patients on hemodialysis is associated with impaired immunity [54]. Patients with repetitive cyst infection are often malnourished with low albuminemia, so it may be important to maintain a good nutrition state in order to ameliorate impaired immunity and prevent cyst infection. More research on this topic is needed as well.

Renal TAE may be effective for preventing cyst infection in terms of blocking the hematogenous spread of bacteria and improving the nutrition status, and we should continue our research on this. Massive hepatomegaly is the strongest factor influencing severe cyst infection, so it is important to prevent massive enlargement of the liver.

Limitation

Our treatment strategy is based on our experience at Toranomon Hospital. The clinical characteristics of the patients with cyst infection, causative bacteria for cyst infection and their susceptibility to antibiotics vary among facilities. Therefore, our strategies cannot be generalized. The treatment strategy should be optimized to each facility according to the background characteristics.

Acknowledgements This work was supported by JSPS KAKENHI Grant Number JP19K17758. This study was also supported in part by a Grant-in-Aid for Progressive Renal Disease Research from the Ministry of Health, Labour and Welfare of Japan and by Okinaka Memorial Institute for Medical Research, Toranomon Hospital. This manuscript was checked for language content by a native English-speaking medical editor at Mr. Brian Quinn, Japan Medical Communication Inc. (Tokyo, Japan).

Compliance with ethical standards

Conflict of interest None

Human and animal rights Not applicable

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Suwabe T, Shukoor S, Chamberlain AM, Killian JM, King BF, Edwards M, Senum SR, Madsen CD, Chebib FT, Hogan MC, Cornec-Le Gall E, Harris PC, Torres VE. Epidemiology of autosomal dominant polycystic kidney disease in olmsted county. Clin J Am Soc Nephrol. 2020;15:69–79.
2. Torres VE. Polycystic kidney disease autosomal-dominant and recessive forms. Philadelphia: Lippincott Williams & Wilkins; 2001.
3. Schwab SJ, Bandor SJ, Klahr S. Renal infection in autosomal dominant polycystic kidney disease. Am J Med. 1987;82:714–8.
4. Gardner KD Jr, Evan AP. Cystic kidneys: an enigma evolve. Am J Kidney Dis. 1984;3:403–13.
5. Sallee M, Rafat C, Zahar JR, Paulmier B, Grunfeld JP, Knebelmann B, Fakhouri F. Cyst infections in patients with autosomal dominant polycystic kidney disease. CJASN. 2009;4:1183–9.
6. Suwabe T, Ubara Y, Higa Y, Nakanishi S, Sagawa Y, Nomura K, Nishimura H, Hoshino J, Sawa N, Katori H, Takemoto F, Nakamura M, Tomikawa S, Hara S, Takiichi K. Infected hepatic and renal cysts: differential impact on outcome in autosomal dominant polycystic kidney disease. Nephron Clin Pract. 2009;112:e157–63.
7. Hattori Y, Hoshino J, Suwabe T, Sumida K, Mise K, Hayami N, Sawa N, Takiichi K, Ubara Y. Umbilical hernia in autosomal dominant polycystic kidney disease. Clin Experim Nephrol. 2015;19:154–6.
8. Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Oland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC, Conference P. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney Disease: Improving Global Outcomes (KDOQI) Controversies Conference. Kidney Int. 2015;88:17–27.
9. Lantinga MA, Castelein NF, Geudens A, de Sevaux RG, van Assen S, Leilveld AM, Gansevoort RT, Drenth JP, Consortium D. Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review. Nephrol Dial Transplant. 2017;32:144–50.
10. Suwabe T, Ubara Y, Mise K, Ueno T, Sumida K, Yamanouchi M, Hayami N, Hoshino J, Kawada M, Imafuku A, Hiramatsu R.
Hasegawa E, Sawa N, Takaichi K. Suitability of Patients with Autosomal Dominant Polycystic Kidney Disease for Renal Transcatheter Arterial Embolization. JASN. 2016;27:2177–87.

Hoshino J, Ubara Y, Suwabe T, Sumida K, Hayami N, Mise K, Hiramatsu R, Hasegawa E, Yamanoouchi M, Sawa N, Takei R, Takaichi K. Intravascular embolization therapy in patients with enlarged polycystic liver. Am J Kidney Dis. 2014;63:937–44.

Hahn ST, Park SH, Lee JM, Kim CY, Chang YS. Renal artery embolization controls intractable pain in a patient with polycystic kidney disease. Cardiovasc Intervent Radiol. 1999;22:422–4.

Morishita H, Yamagami T, Takeuchi Y, Matsumoto T, Asai S, Nakanouchi T, Sato O, Nishimura T. Use of N-butyl-2-cyanoacrylate for transcatheter arterial embolization of renal arteries in patients with polycystic kidney disease. JVIR. 2011;22:1631–3.

Mukai T, Mipuma H, Gobara H, Shimizu M, Niiya H, Kanazawa S. A case of renal transcatheter arterial embolization with ethanol in autosomal dominant polycystic kidney disease for volume reduction. Acta Medica Okayama. 2011;65:347–51.

Kim H, Jung GS, Jung YS. Transcatheter arterial embolization using ethanol in a dialysis patient for contracting enlarged polycystic kidneys. Korean J Radiol. 2010;11:574–8.

Sakuraba Y, Kato F, Abo D, Hasegawa Y, Shimizu T, Terae S, Shirato H. Transcatheter arterial embolization with absolute ethanol injection for enlarged polycystic kidneys after failed metallic coil embolization. JVIR. 2008;19:267–71.

Petitpierre F, Cornelis F, Couzi L, Lhommel R, Devuyst O, Annet L, Pirson Y, Hasmat H, Jouret F, Marthand R, Ducassou D. The effect of renal failure on 18F-FDG uptake: a theoretic assessment. J Nucl Med Technol. 2008;36:200–2.

Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo Y, Hasegawa E, Shimaoka N, Takemoto F, Takaichi K. The renal cyst infection caused by Salmonella enteritidis in a patient with autosomal dominant polycystic kidney disease: how did this pathogen come into the renal cysts? Clin Experimen Nephrol. 2011;15:151–3.

Bennett WM, Elzinga L, Pulliam JP, Rashad AL, Barry JM. Cyst fluid antibiotic concentrations in autosomal-dominant polycystic kidney disease. Am J Kidney Dis. 1985;6:400–4.

Müther RS, Bennett WM. Cyst fluid antibiotic concentrations in polycystic kidney disease: differences between proximal and distal cysts. Kidney Int. 1981;20:519–22.

Schwab S, Hinthorn D, Diederich D, Cuppage F, Grantham J. PH-dependent accumulation of clindamycin in a polycystic kidney. Am J Kidney Dis. 1983;3:63–6.

Elzinga LW, Golper TA, Rashad AL, Carr ME, Bennett WM. Ciprofloxacin activity in cyst fluid from polycystic kidneys. Antimicrob Agent Chemotherapy. 1988;32:844–7.

Hiyama L, Tang A, Miller LG. Levofloxacin penetration into a renal cyst in a patient with autosomal dominant polycystic kidney disease. Am J Kidney DIS. 2006;47:e9–13.

Rossi SJ, Healy DP, Savani DV, Deepe G. High-dose ciprofloxacin in the treatment of a renal cyst infection. Annal Pharmacotherapy. 1993;27:389–93.

Schwab SJ, Weaver ME. Penetration of trimethoprim and sulfamethoxazole into cysts in a patient with autosomal-dominant polycystic kidney disease. Am J Kidney Dis. 1986;7:434–8.

Truven Health Analytics I. Dosing information: dosage in renal failure. DRUGDEX®2014.

Hamanooue S, Suwabe T, Ubara Y, Kikuchi K, Hayashi R, Mise K, Ueno T, Takaichi K, Matsumoto K, Morita K. Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts. BMC Nephrol. 2018;19:272.

Hamanooue S, Suwabe T, Ubara Y, Kikuchi K, Hayashi R, Mise K, Ueno T, Takaichi K, Matsumoto K, Morita K. Cyst infection in autosomal dominant polycystic kidney disease: differences between proximal and distal cysts. Kidney Int. 2012;27:3746–51.

Tsuchiya Y, Ubara Y, Suwabe T, Hoshino J, Yamanoouchi M, Hayami N, Marui Y, Sawa N, Takei R, Takaichi K. Intravascular embolization therapy in patients with enlarged polycystic liver. Am J Kidney Dis. 2014;63:937–44.

Hoshino J, Ubara Y, Suwabe T, Hoshino J, Yamanoouchi M, Hayami N, Marui Y, Sawa N, Takei R, Takaichi K. Intravascular embolization therapy in patients with enlarged polycystic liver. Am J Kidney Dis. 2014;63:937–44.

Hoshino J, Ubara Y, Suwabe T, Hoshino J, Yamanoouchi M, Hayami N, Marui Y, Sawa N, Takei R, Takaichi K. Intravascular embolization therapy in patients with enlarged polycystic liver. Am J Kidney Dis. 2014;63:937–44.
42. Novelli A, Fallani S, Cassetta MI, Conti S. Pharmacokinetics and pharmacodynamics of oral cephalosporins as critical factors in choice of antibiotics. Int J Antimicrob Agents. 2000;16:501–5.

43. Morita A, Kamei S, Minami M, Yoshida K, Kawabata S, Kuroda H, Suzuki Y, Araki N, Iwasaki Y, Kobayashi R, Hayashi N, Hirayama T, Ochiai J, Ueda M, Yamagishi Y, Niwa J, Shindo K, Fukushima Y, Takita T, Sato T, Sato S, Mikamo H, Iwata S. Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan. J Infec Chemotherapy. 2014;20:535–40.

44. Chapman AB, Thickman D, Gabow PA. Percutaneous cyst puncture in the treatment of cyst infection in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1990;16:252–5.

45. Harris PC, Torres VE. Polycystic kidney disease, Autosomal Dominant. In: Adam MP, editor. GeneReviews®[Internet]. Seattle: University of Washington; 2015.

46. Ubara Y, Tagami T, Sawa N, Katori H, Yokota M, Takemoto F, Inoue S, Kuzuhaara K, Hara S, Yamada A. Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients. Am J Kidney Dis. 2002;39:571–9.

47. Yamanouchi M, Ubara Y, Takaichi K. Emphysematous cyst infection in autosomal dominant polycystic kidney disease. Clin Expim Nephrol. 2012;16:505–6.

48. Baumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature. 2016;535:85–93.

49. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535:65–74.

50. Boirivant M, Amendola A, Butera A. Intestinal microflora and immunoregulation. Mucosal Immunol. 2008;1(Suppl 1):S47–9.

51. Kotani Y, Kunisawa J, Suzuki Y, Sato I, Saito T, Toba M, Kohda N, Kiyono H. Role of Lactobacillus pentosus Strain b240 and the Toll-like receptor 2 axis in Peyer’s patch dendritic cell-mediated immunoglobulin A enhancement. PLoS One. 2014;9:e91857.

52. Katona P, Katona-Apte J. The interaction between nutrition and infection. Clin Infect Dis. 2008;46:1582–8.

53. Keusch GT. The history of nutrition: malnutrition, infection and immunity. J Nutr. 2003;133:336S–40S.

54. Muraya Y, Oozono Y, Kadota JI, Miyazaki M, Hashimoto A, Iida K, Kawakami K, Shirai R, Kaku M, Koga H, Harada T, Kohno S, Hara K. Clinical and Immunological Evaluation of Infection in Patients on Hemodialysis. J Infec Chemotherapy. 1996;2:247–53.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.